NCT04979520

Molecular Characteristics of Brodalumab in Hidradenitis Suppurativa

A Small Pilot Study to Develop Biomarkers of Weekly Brodalumab Administration in Hidradenitis Suppurativa Patients

• Status: Completed
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 4 (actual)
• Sponsor: Rockefeller University · Academic / Other
• Sex: All
• Age: 18 Years – 99 Years
• Healthy volunteers: Not accepted

Summary

Hidradenitis suppurativa is a disease involving skin folds, causing swelling of the skin and surrounding tissues, pain, and foul-smelling discharges. Effective treatment options are lacking. Recently, clinical trials conducted in our lab found Brodalumab was an effective drug for this disease. Weekly dosing achieved superior therapeutic outcomes compared to a dosing given once in every other week. Brodalumab was safe in both regimens, but blood and tissue studies to better understand this response are still needed. By performing this small pilot study and collecting blood and tissue samples from participants treated with Brodalumab once weekly we would like to better characterize the molecular response to this treatment, identify blood and tissue markers reflecting disease severity, and better understand disease mechanisms.

Conditions

• Hidradenitis Suppurativa
• Acne Inversa

Interventions

Type	Name	Description
DRUG	Brodalumab	Subcutaneously Brodalumab/Siliq, 210mg/1.5ml once a week

Timeline

• Start date: 2021-08-05
• Primary completion: 2022-07-25
• Completion: 2022-07-25
• First posted: 2021-07-28
• Last updated: 2022-07-27

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study